Literature DB >> 6721472

In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates.

P C Fuchs, A L Barry, C Thornsberry, R N Jones.   

Abstract

A total of 632 clinical bacterial isolates were tested for susceptibility to twofold dilutions of ticarcillin alone and in combination with 1, 2, and 4 micrograms of clavulanic acid (CA) (Timentin) per ml by a reference microdilution method. With the addition of CA, ticarcillin MICs were reduced eightfold or greater with 54 of 59 (92%) strains of the family Enterobacteriaceae with ticarcillin MICs of greater than or equal to 64 micrograms/ml. The inhibitory effect of CA on pseudomonads was minimal. Ticarcillin MICs for beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, and most Staphylococcus aureus were reduced to less than or equal to 0.5 micrograms/ml when CA was added. For dilution susceptibility testing of ticarcillin-clavulanic acid, dilutions of ticarcillin combined with 2 micrograms of CA per ml is suggested.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721472      PMCID: PMC185529          DOI: 10.1128/AAC.25.3.392

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro antimicrobial activity of piperacillin and seven other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase producing strains.

Authors:  C Thornsberry; C N Baker; R N Jones
Journal:  J Antimicrob Chemother       Date:  1979-03       Impact factor: 5.790

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

3.  An in vitro evaluation of clavulanic acid, a potent, broad-spectrum beta-lactamase inhibitor.

Authors:  D Greenwood; F O'Grady; P Baker
Journal:  J Antimicrob Chemother       Date:  1979-09       Impact factor: 5.790

4.  Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli.

Authors:  J W Paisley; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

5.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

6.  Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

7.  Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins.

Authors:  P C Fuchs; C Thornsberry; A L Barry; T L Gavan; E H Gerlach; R N Jones
Journal:  J Antibiot (Tokyo)       Date:  1977-12       Impact factor: 2.649

8.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

9.  Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

10.  In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits.

Authors:  P C Fuchs; A L Barry; C Thornsberry; T L Gavan; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

View more
  21 in total

1.  Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa.

Authors:  F A Manian; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

2.  Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa.

Authors:  F Tausk; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 3.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

4.  [Pharmacokinetics of betabactyl in the field of gynecology].

Authors:  D v Kobyletzki; C A Primavesi; H D Heilmann; A Wieczorek; J Hofmann
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

5.  Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid.

Authors:  P C Fuchs; R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

6.  Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.

Authors:  A S Beale; J Gisby
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

7.  Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.

Authors:  G L Jungbluth; D L Cooper; G D Doyle; G M Chudzik; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Bactericidal effects of ticarcillin-clavulanic acid against beta-lactamase-producing bacteria in vivo.

Authors:  R J Boon; A S Beale; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

9.  Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

10.  Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.